The use of metformin and colorectal cancer incidence in patients with type ii diabetes mellitus

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1877-1883

  Smiechowski, Brielan ^a,b   Azoulay, Laurent ^a,c   Yin, Hui ^a   Pollak, Michael N ^c   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Departments of Epidemiology Biostatistics and Occupational Health   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GUAR GUM; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEGLITINIDE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER INCIDENCE; CASE CONTROL STUDY; CHOLECYSTECTOMY; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGMOIDOSCOPY; TREATMENT DURATION;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN;

EID: 84886416382     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0196     Document Type: Article

References (24)

1. Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86.
2. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010;3:1060-5.
3. Ioannou GN, Boyko EJ. Metformin and colorectal cancer risk in diabetic patients. Diabetes Care 2011;34:2336-7.
4. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/- mice. Cancer Sci 2008;99:2136-41.
5. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52: 1766-77.
6. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.
7. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, KimWH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012;131:752-9.
8. Tseng CH. Diabetes, metformin use, and colon cancer: a populationbased cohort study in Taiwan. Eur J Endocrinol 2012;167:409-16.
9. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044-50.
10. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 2008;51:593-7.
11. Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:923-9.
12. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2012; 21:280-6.
13. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a shortterm clinical trial. Cancer Prev Res (Phila) 2010;3:1077-83.
14. Meyerhardt JA. Exercise and metformin in colorectal cancer survivors. ClinicalTrials gov: NCT01340300; 2013.
15. Tufts Medical Center. Impact of pretreatment with metformin on colorectal cancer stem cells (CCSC) and related pharmacodynamic markers. ClinicalTrials gov: NCT01440127; 2013.
16. Wong V. A trial of metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index. ClinicalTrials gov: NTC01312467; 2013.
17. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
18. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128-36.
19. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005;3: 587-94.
20. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011;34:2323-8.
21. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-73.
22. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-9.
23. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010;49:662-71.
24. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003;158:915-20.